About this trial
The aim of this study is to evaluate the impact of artificial intelligence (AI) assistance during routine upper endoscopy on gastric cancer-specific mortality. We hypothesize that AI-assisted endoscopic interpretation can further reduce gastric cancer-related mortality through two mechanisms: (1) improved detection of H. pylori infection, facilitating timely eradication therapy and subsequent prevention of gastric carcinogenesis; and (2) earlier identification of premalignant gastric conditions, enabling appropriate surveillance endoscopy and earlier detection of gastric cancer. The primary endpoint is gastric cancer-specific mortality.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 20-80
Scheduled endoscopy
Disqualifiers
None
Trial population
This study will invite patients who need to undergo upper gastrointestinal endoscopy.
Trial design
Cohort
Prospective
Treatments tested in this trial
Routine endoscopy with artificial intelligence-assisted interpretation
Other intervention(1) Improved detection of H. pylori infection, leading to timely eradication therapy. (2) Earlier identification of premalignant gastric conditions, facilitating appropriate surveillance endoscopy.
Treatment groups
Trial outcomes
Primary outcomes
Gastric cancer-specific mortality
The primary endpoint is gastric cancer-specific mortality.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.